A5040956966- Acute Myeloid Leukemia Research
- Cancer Genomics and Diagnostics
- Protein Degradation and Inhibitors
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Multiple Myeloma Research and Treatments
- Epigenetics and DNA Methylation
- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Retinoids in leukemia and cellular processes
- Healthcare Operations and Scheduling Optimization
- MicroRNA in disease regulation
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- RNA Research and Splicing
- Immunodeficiency and Autoimmune Disorders
- Advanced biosensing and bioanalysis techniques
- Glioma Diagnosis and Treatment
- Cancer-related gene regulation
- RNA Interference and Gene Delivery
- Single-cell and spatial transcriptomics
Charité - Universitätsmedizin Berlin
2013-2025
German Cancer Research Center
2010-2025
Freie Universität Berlin
2018-2025
Humboldt-Universität zu Berlin
2018-2025
Heidelberg University
2013-2025
German Cancer Society
2019-2025
Berlin Institute of Health at Charité - Universitätsmedizin Berlin
2018-2025
German Marine Research Consortium
2020-2025
Deutschen Konsortium für Translationale Krebsforschung
2019-2025
University Hospital Heidelberg
2006-2025
Recent studies have provided a detailed census of genes that are mutated in acute myeloid leukemia (AML). Our next challenge is to understand how this genetic diversity defines the pathophysiology AML and informs clinical practice.
Fluorescence in situ hybridization has improved the detection of genomic aberrations chronic lymphocytic leukemia. We used this method to identify chromosomal abnormalities patients with leukemia and assessed their prognostic implications.Mononuclear cells from blood 325 were analyzed by fluorescence for deletions chromosome bands 6q21, 11q22-23, 13q14, 17p13; trisomy 3q26, 8q24, 12q13; translocations involving band 14q32. Molecular cytogenetic data correlated clinical findings.Chromosomal...
Mutations occur in several genes cytogenetically normal acute myeloid leukemia (AML) cells: the nucleophosmin gene (NPM1), fms-related tyrosine kinase 3 (FLT3), CCAAT/enhancer binding protein α (CEPBA), myeloid–lymphoid or mixed-lineage (MLL), and neuroblastoma RAS viral oncogene homolog (NRAS). We evaluated associations of these mutations with clinical outcomes patients.
In patients with acute myeloid leukemia (AML), the presence or absence of recurrent cytogenetic aberrations is used to identify appropriate therapy. However, current classification system does not fully reflect molecular heterogeneity disease, and treatment stratification difficult, especially for intermediate-risk AML a normal karyotype.
Purpose To analyze the frequency and prognostic impact of isocitrate dehydrogenase 1 (IDH1) 2 (IDH2) mutations in acute myeloid leukemia (AML). Patients Methods We studied 805 adults (age range, 16 to 60 years) with AML enrolled on German-Austrian Study Group (AMLSG) treatment trials HD98A APL HD95 for exon 4 IDH1 IDH2. were also NPM1, FLT3, MLL, CEBPA mutations. The median follow-up survival was 6.3 years. Results IDH found 129 patients (16.0%) —IDH1 61 (7.6%), IDH2 70 (8.7%). Two had both...
The tet oncogene family member 2 (TET2) gene was recently identified to be mutated in myeloid disorders including acute leukemia (AML). To date, there is increasing evidence for a functional role of TET2 mutations (TET2(mut)) AML. Thus, we explored the frequency, gene-expression pattern, and clinical impact TET2(mut) large cohort patients with AML context other AML-associated aberrations.Samples from 783 younger adult were analyzed presence (coding exons 3 11), results correlated data...